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eta-Blockers in Hypertension
dding Insult to Injury*
orman M. Kaplan, MD
allas, Texas
eta-blockers have been found not to be effective for
rimary prevention of cardiovascular disease in patients with
rimary hypertension. The problem was first recognized by
esserli et al. (1) in 1998. They pointed out the signifi-
antly lesser benefit of beta-blocker therapy in 2 trials versus
iuretic-based therapy in 7 separate trials. Their presenta-
ion could not have been clearer: “Diuretic therapy was
uperior to blockade with regard to all end points. . .
-blocker therapy only reduced the odds for cerebrovascular
vents but was ineffective for preventing coronary heart
isease, cardiovascular mortality and all-cause mortality.”
See page 1482
This clear distinction was not referenced in the 2003 Joint
ational Committee (JNC) report (2), which favored a
iuretic for first drug but indicated that beta-blockers were
uitable alternatives, particularly when a “compelling” indi-
ation was present, including heart failure, post-myocardial
nfarction, high coronary disease risk, or diabetes mellitus.
A few months after the 2003 JNC report was published,
esserli et al. (3), with 3 well-established hypertension ex-
erts, said it again, even more clearly: “The time has come to
dmit that beta-blockers should no longer be considered appro-
riate for first-line therapy of uncomplicated hypertension.”
he British and European Hedges
ven after this indictment, however, the 2004 British
ypertension Society (BHS) guidelines (4) put beta-
lockers alongside angiotensin-converting enzyme inhibi-
ors (ACEIs) and angiotensin II receptor blockers (ARBs)
s initial therapy for hypertensive patients under age 55
ears and for nonblack patients. The 2004 BHS guidelines
id, however, hedge their position, stating that according to
heir AB/CD algorithm, either an ACEI or an ARB (A) or
beta-blocker (B) should be chosen for younger and
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ivision, Dallas, Texas.onblack patients whereas either a calcium-channel blocker
C) or a diuretic (D) should be chosen for patients who are
ver age 55 years or black, but the algorithm does place the
B” in brackets. The report says, “the reason is to emphasize
he fact that recent trials have reported an increase in onset
f diabetes in patients treated with B or D drugs compared
ith A or C drugs, especially when B and D are combined.
e advise caution when using BD in patients at especially
igh risk of developing diabetes as for example, patients
ith a strong family history of type 2 diabetes, obesity,
mpaired glucose tolerance, features of metabolic syndrome
r of South Asian and African-Caribbean descent” (4).
Note that the warning did not relate to the lesser benefit
f beta-blockers in general, only to their propensity to bring
ut diabetes.
The British did amend their position in a statement on
heir website on June 28, 2006, providing a new algorithm
ithout a B (beta-blocker) anywhere to be found and
ncluding the statement that “beta-blockers are no longer
referred as a routine initial therapy for hypertension” (5).
This good advice, however, did not get through to the
riters of the 2007 European Society of Hypertension and
uropean Society of Cardiology guidelines (6). They stated:
Beta-blockers may still be considered an option for initial
nd subsequent antihypertensive treatment strategies. Be-
ause they favor an increase in weight, have adverse effects
n lipid metabolism and increase (compared with other
rugs) the incidence of new-onset diabetes, they should not
e preferred, however, in hypertensives with multiple met-
bolic risk factors including the metabolic syndrome. . .” (6).
he Swedish Explosion
esserli et al. (7) said it again in 2007, in this Journal,
dding a litany of side effects from beta-blockers, including:
) precipitation of diabetes; 2) little effect on regression of
eft ventricular hypertrophy; 3) likely failure to improve
ndothelial function; 4) weight gain; and 5) decrease in
xercise endurance.
To emphasize their position, they added: “For every
yocardial infarction or stroke prevented in the Medical
esearch Council study (8), 3 patients treated with atenolol
ithdrew from the study secondary to impotence and
nother 7 withdrew because of fatigue” (7).
Despite the persistence of Messerli et al. (1), the beta-
locker atenolol was the fourth most prescribed drug in the
.S. in 2005, with 44 million prescriptions per year (7). It
equired 2 papers in the Lancet from 3 Swedish authors
9,10), with their accompanying editorials, to bring the issue
o the currently almost unanimous agreement that beta-
lockers are no longer an appropriate choice for initial or, as
tated in the 2006 BHS addendum, subsequent therapy of
ncomplicated hypertension. In retrospect, it took the
xhortation of Messerli et al. (1) to set the stage but, perhaps
ith Americans being generally less accepted in the rest of
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October 28, 2008:1490–1 Beta-Blockers in Hypertensionhe world these days, it took the Swedes to lower the
urtain.
Rather surprisingly, in view of the prior analyses by
esserli et al. (1) showing equal protection against stroke by
eta-blockers, the problem shown by the Swedish meta-
nalyses was lesser protection against strokes by beta-
lockers.
he Additional Blow
he paper by Bangalore et al. (11) in this issue of the Journal
dds another post-mortem explanation for the fall of beta-
lockers, showing higher mortality associated with the
lower heart rate they induce. Of interest, the fall in pulse
ate is an obvious mechanism for the higher central blood
ressure with beta-blocker–based therapy noted by Williams
t al. (12) in the CAFE (Conduit Artery Function Evaluation)
tudy. With this addition to the evidence, beta-blockers will
urely remain as indicated for heart failure, for after myocardial
nfarction, and for tachyarrhythmias, but no longer for hyper-
ension in the absence of these compelling indications.
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